Oslo/London - 3 December 2021: Reference is made to the Notice of Extraordinary
General Meeting of Exact Therapeutics AS ("EXACT-Tx", or "the Company" Euronext
Growth: EXTX) published on 25 November 2021.
The Extraordinary General Meeting of the Company was held today via video
conference. All resolutions were passed in line with the proposals from the
Board of Directors and the Nomination Committee, as published on 25 November
2021. Please find enclosed the Minutes from the Meeting.
Anders Wold was elected as a new Board Member in the Company and will replace
Hans Henrik Klouman. Accordingly, the Board of Directors consists of Chair Masha
Strømme, Vice-Chair William Castell and Board Members Jean Claude Provost,
Anders Wold, Jean Michel Cossery, Aitana Peire and Ann-Tove Kongsnes.
Information on the Members of the Board of Directors of the Company can be found
on https://www.exact-tx.com.
It was further resolved that Anders Wold shall receive an annualized
compensation of NOK 180,000, in addition to annualized remuneration of NOK
20,000 as Member of the Audit Committee.
A copy of the Minutes are attached to this Notice.
For more information contact:
Dominic Moreland
CEO EXACT Therapeutics
Email: dominic@exact-tx.com
www.exact-tx.com
About EXACT-Tx:
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology
platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®).
ACT® follows a unique approach to ultrasound-mediated, targeted drug enhancement
- with the potential to significantly amplify the clinical utility of a wide
range of therapeutic agents across a multitude of indications including within
oncology (chemotherapy, immunotherapy), infectious diseases, and brain diseases.